Q-omics provides the consensus-scored KLHL35 profile across patient tissues and cancer cell-line models. KLHL35 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, KLHL35 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, KLHL35 RNA expression shows 14,914 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, COAD, and TGCT as cancer lineages where KLHL35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLHL35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLHL35 survival associations across molecular data types. KLHL35 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLHL35 RNA expression–survival associations across cancer types. High KLHL35 expression shows unfavorable associations in ACC, but favorable associations in HNSC, LUAD, LGG, UVM and READ. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for KLHL35 RNA expression.
This table summarizes KLHL35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for KLHL35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLHL35 shows lower tumor expression in KICH and higher tumor expression in COAD, BLCA, BRCA, UCEC and STAD. The COAD box plot shows higher KLHL35 RNA expression in tumor versus normal tissue (log2 FC = +2.162, t-test p < 0.001).
This table shows molecular features associated with KLHL35 in patient tissues and cancer cell lines. In patient samples, KLHL35 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KLHL35 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and OESOPHAGUS.
